SCHEMBL3490684

SCHEMBL3490684

CSc1ccc(CCl)cc1C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.40
PYCR1 P32322 1/20 0.37
CCR2 P41597 2/20 0.35
GPR84 Q9NQS5 1/20 0.34
NOTUM Q6P988 1/20 0.33
ADRA2A P08913 1/20 0.32
ADRA2B P18089 1/20 0.32
ADRA2C P18825 1/20 0.32
ADRA1D P25100 1/20 0.32
ADRA1A P35348 1/20 0.32
ADRA1B P35368 1/20 0.32
AR P10275 2/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
PTPN7 P35236 2/20 0.31
DUSP3 P51452 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12059552 0.84 IDO1 (0.38) IDO1PYCR1CCR2ADRA2AADRA2B
SCHEMBL13461942 0.82 IDO1 (0.37) IDO1PYCR1CCR2NOTUMADRA2A
SCHEMBL13461854 0.82 IDO1 (0.37) IDO1PYCR1CCR2NOTUMADRA2A
SCHEMBL3491800 0.82 KIF11 (0.44) IDO1PYCR1CCR2ARPTPN7
SCHEMBL17295109 0.79 IDO1 (0.35) IDO1PYCR1CCR2ADRA2AADRA2B
SCHEMBL2092880 0.78 IDO1 (0.44) IDO1PYCR1CCR2ADRA2AADRA2B
SCHEMBL932921 0.77 IDO1 (0.62) IDO1PYCR1GPR84NOTUM
SCHEMBL29560777 0.77 PTPN7 (0.45) IDO1ARCYP3A4CYP2D6CYP2C9
SCHEMBL1717487 0.77 PTPN7 (0.45) IDO1ARCYP3A4CYP2D6CYP2C9
SCHEMBL7786392 0.77 TTR (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492378-B2 GSK-3β inhibitor TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-23 US disclosed
US-20100069381-A1 GSK-3BETAINHIBITOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069381-A1 GSK-3BETAINHIBITOR GSK3B, GSK3A, GSKIP IDO1 1290/4885PYCR1 2780/4885CCR2 3853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.